Sanofi (SNY) Expected to Announce Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 31st. Analysts expect Sanofi to post earnings of $0.98 per share and revenue of $9.91 billion for the quarter.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. Sanofi's quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.78 EPS. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Price Performance

NASDAQ:SNY traded up $0.24 during mid-day trading on Friday, reaching $50.37. The stock had a trading volume of 1,468,581 shares, compared to its average volume of 2,528,303. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. Sanofi has a one year low of $45.80 and a one year high of $60.12. The firm has a 50 day moving average price of $49.57 and a two-hundred day moving average price of $52.10. The stock has a market capitalization of $123.53 billion, a P/E ratio of 17.99, a P/E/G ratio of 1.14 and a beta of 0.48.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC grew its stake in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company's stock worth $1,693,000 after purchasing an additional 15,791 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company's stock worth $2,732,000 after purchasing an additional 752 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the company. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.